KING OF PRUSSIA, PA, and CARY, NC — United BioSource LLC (UBC) and Thread® recently announced the expansion of their SitePlus solution. This joint offering, born from a six-year collaboration, has shown early success in recruitment and retention for biopharma customers since its launch in March 2023. The expanded solution now includes additional central site services and technology features tailored for both post-approval research and Phase II/III interventional clinical trials.
SitePlus offers a revolutionary research model that can be implemented from the initial study design phase or integrated into ongoing Phase II-IV studies nationwide. By providing a central site model, SitePlus extends the reach of clinical sites and broadens the patient population accessible for trials. The solution employs a centralized technology platform to expedite patient recruitment, facilitate home health engagement, securely capture data, and improve patient retention.
The collaboration combines UBC’s expertise in late-stage research with Thread’s technological capabilities. This synergy creates central site study designs that are patient-centric while enhancing the research experience for participating sites. It also allows biopharma sponsors to contract with UBC as a central research center, including investigator and study coordinating center concierge support services. SitePlus integrates UBC’s central principal investigator, home health services, and patient coordinating center expertise with Thread’s unified technology platform for data capture, virtual visits, and optimized patient engagement.
“Study designs that rely exclusively on brick-and-mortar site models can benefit from the enhancements SitePlus offers to help meet their patient enrollment and retention goals,” said Bekki Bracken Brown, President & Chief Executive Officer of UBC. “Studies leveraging a hybrid approach have seen success in reaching a more representative patient population, faster, and maintaining patient engagement. The Thread technology platform supports our central site offering by enabling a more flexible approach to patient recruitment and engagement and strengthens the return on evidence generation for our customers.”
Thread Co-Founder and CEO John Reites expressed enthusiasm for the expansion: “Based on strong early results with SitePlus for our joint customers, we are excited to expand its features to offer solutions in both interventional and post-approval research studies. We appreciate UBC’s continued partnership and the feedback from our biopharma customers to add more value to this important innovative offering’s market growth.”
The expanded SitePlus solution aims to enhance clinical trial efficiency, making it easier to meet patient enrollment and retention targets while delivering robust evidence generation.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and Microsoft Start.